microbiome
Thank you for visiting us!
Please note that this website is not intended for end consumers, as the information provided here refers only to ingredients and not to finished products. The content on this website is intended exclusively for manufacturers of foods, beverages, dietary supplements, and cosmetic products.
This website is available in multiple countries worldwide; therefore, it may contain statements or product classifications that do not apply to your country. This website uses technical, analytical, and third-party cookies. By continuing to browse, you agree to the terms stated above.
About Us
TGD is an innovative SME specialized in the research and development of innovative ingredients for dietary supplements based on essential oils. The combination of entrepreneurial spirit, scientific research, and internationally recognized clinical experience is a key strength of TGD and forms the foundation for establishing a leadership position in the nutraceutical market based on essential oils.
Publications
Timeline
2014 – Start Cup Emilia-Romagna
The TGD project wins the Start Cup Emilia-Romagna, the regional business plan competition for universities and research centers, as the best entrepreneurial project. The project was born from a long professional collaboration and a deep friendship between Prof. Massimo Campieri, one of the world’s leading experts in the field of chronic inflammatory bowel diseases, and Prof. Enzo Spisni, Associate Professor at the University of Bologna, specializing in gastrointestinal physiology and human nutrition.
2015 – The foundation of TGD s.r.l.
With the support of the University of Bologna and several investors, the project takes shape and becomes a startup.
2017 – The First Clinical Study
The funds raised from investors are used for the first pilot clinical study on BIOintestil®, the first ingredient of TGD, followed by a randomized double-blind placebo-controlled study, published in 2022.
2020 – The SPIN Project – Eugedin Complex®
TGD participates in a European EIT Food call for the development of innovative dietary supplements based on natural antiviral principles to support the immune system in the fight against the SARS-CoV-2 pandemic. This leads to the creation of Eugedin Complex®, an ingredient produced and marketed by TGD from the following year.
2021 – Limenorm®
The first preclinical studies on Limenorm® are published, a product dedicated to modulating the intestinal microbiome in subjects with metabolic syndrome and/or prediabetes. The randomized double-blind placebo-controlled clinical trial on patients with metabolic syndrome is still ongoing.
2022 – Clovedin® and Algistat®
The first in vitro study on Clovedin® is published, a product dedicated to women for the prevention of vaginal candidiasis. The following year, the randomized double-blind placebo-controlled pilot clinical study on patients with recurrent vaginal candidiasis begins.
A collaboration with the University of Siena leads to the in vitro experimentation of Algistat®, a natural ingredient designed to provide relief in conditions of chronic pain and neuroinflammation.
2025 – Clinical Study on Algistat® and “Real-Life” Study on BIOintestil®
An open-label interventional clinical study is currently underway on volunteer subjects diagnosed with Fibromyalgia, in collaboration with the Italian Association of Fibromyalgia Patients (CFU – Comitato Fibromialgici Uniti). Two preclinical studies are also in progress to evaluate the efficacy of Algistat® in modulating neuroinflammation, a phenomenon associated with neuropathic pain.
At the beginning of the year, the first open-label interventional study was published, conducted on 1,585 patients using a dietary supplement based on BIOintestil®.
Request our consultation
We also offer consultancy services for in vitro and preclinical studies, and the formulation of nutraceutical products based on essential oils
